NCT04654208Completed
Swedish Ibrance Registries Insights (SIRI)
PALBOCICLIB TREATMENT PATTERNS IN SWEDISH PATIENTS WITH METASTATIC BREAST CANCER - SWEDISH IBRANCE REGISTRIES INSIGHTS (SIRI)
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1500 (actual)
- First submitted
- 27 Nov 2020
- Start date
- 15 Dec 2020
- Primary completion date
- 31 May 2026
- Lead sponsor
- Pfizer
- Diseases
- Metastatic breast cancer
- NCT number
- NCT04654208
What you commit to
- Study type: Observational
- Participants enrolled: 1500
- From 15 Dec 2020 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no exclusion criteria
Who the study is looking for
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
- Age ≥18 years at index date
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Sweden Coordinator of this site? Confirm its status | Sollentuna | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.